Vlado Perkovic's Publications

Rossing P, Baeres FMM, Bakris G et alii
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Journal articles
2023
Nephrol Dial Transplant
Singh AK, Causland FRM, Claggett BL et alii
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials.
Journal articles
2022
Nephrol Dial Transplant
Ridker PM, Tuttle KR, Perkovic V et alii
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
Journal articles
2022
European heart journal
Hammett C, Badve SV, Kerr PG et alii
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice
Journal articles
2022
Heart Lung and Circulation
Tye SC, Jongs N, Coca SG et alii
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Journal articles
2022
Cardiovascular Diabetology
Nunes JC, Yu J, Arnott C et alii
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program
Journal articles
2022
Diabetes
Kolkailah AA, Marx N, Rosenstock J et alii
Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin
Journal articles
2022
Circulation
Mathur VS, Bushinsky DA, Inker L et alii
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis
Journal articles
2022
NEPHROLOGY DIALYSIS TRANSPLANTATION
Sarraju A, Bakris G, Cannon CP et alii
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Journal articles
2022
Journal of the American College of Cardiology
Koshino A, Schechter M, Sen T et alii
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Journal articles
2022
Diabetes Care
Smeijer JD, Koomen JV, Kohan DE et alii
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease
Journal articles
2022
Clinical Pharmacology and Therapeutics
Perkovic V, Blackorby A, Cizman B et alii
The ASCEND-ND trial: study design and participant characteristics
Journal articles
2022
Nephrology
Singh AK, Acharya A, Carroll K et alii
Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
Journal articles
2022
European Heart Journal
Mahaffey KW, Baeres FMM, Bakris G et alii
Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial
Journal articles
2022
European Heart Journal
McCausland F, Singh A, Claggett B et alii
Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial
Journal articles
2022
European Heart Journal
Kim D, Lv J, Hladunewich M et alii
EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL
Conference Abstracts
2022
in NEPHROLOGY
Neuen B, Fletcher R, Arnott C et alii
CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL
Conference Abstracts
2022
in NEPHROLOGY
Li C, Yu J, Hockham C et alii
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Journal articles
2022
Diabetes
Wong MG, Lv J, Perkovic V
Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply
Journal articles
2022
JAMA
Tye S, Jong N, Coca SG et alii
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure
Conference Abstracts
2022
in DIABETOLOGIA
Schechter M, Koshino A, Jongs N et alii
Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis
Conference Abstracts
2022
in DIABETOLOGIA
Nazarzadeh M, Bidel Z, Canoy D et alii
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Journal articles
2022
The Lancet Diabetes and Endocrinology
Li JW, Arnott C, Heerspink HJL et alii
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Journal articles
2022
Journal of the American Heart Association
Ferrannini E, Baldi S, Scozzaro T et alii
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Journal articles
2022
Diabetes Care
Heerspink HJL, Stack AG, Terkeltaub R et alii
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia
Journal articles
2022
Nephrology Dialysis Transplantation
Kotwal S, Perkovic V, Heerspink HJL
Platform Clinical Trials Within Nephrology—Interpreting the Evidence
Journal articles
2022
American Journal of Kidney Diseases

Vlado Perkovic's Publications

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials.

Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease

The ASCEND-ND trial: study design and participant characteristics

Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL

CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure

Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Platform Clinical Trials Within Nephrology—Interpreting the Evidence

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country